NCT03625960

Cantharone for the Treatment of Perenial Warts

Trichloroacetic Acid Versus Cantharone for the Treatment of Perenial Warts

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Wayne State University · Academic / Other
• Sex: Female
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

Comparison of trichloroacetic acid versus cantharidine for the treatment of perenial warts.

Detailed description

Warts are one of the most common sexually transmitted diseases. They are caused by the human papilloma virus (HPV) that causes cervical cancer. Warts can grow, obstruct labor, and spread. Patients presenting to the obgyn clinic with perenial warts were randomized to treatment with trichloroacetic acid (one of the many types of treatments) or to the treatment with cantharidine group. Cantharidine is a vesicant extracted from beetle bugs which painlessly causes a small blister to form and cures the patient from the HPV infection causing the wart . We compared cosmesis, scar formation, pain and number of treatments (visits) as well as effectiveness in both groups. Objectives 1. Determine if cantharone is more effective than trichloroacetic acid (TCA) for removal of warts 2. Compare pain levels (pain during application) for each method 3. Compare patient satisfaction for each method 4. Compare scar formation and cosmesis for each method

Conditions

• Wart, Genital

Interventions

Type	Name	Description
DRUG	Cantharidin	A thin film of cantharidin is applied to the surface of the wart and to 1 millimeter area surrounding the wart. After the film dries, it is covered with an occlusive dressing for 24 hours. The patient removes the area the next day and thoroughly washes the area with soap and water. Patients return to clinic a week later.
DRUG	Trichloroacetic Acid	Trichloroacetic acid is applied to the surface of the wart with a wooden applicator and after drying the area is washed with soap and water in an hour.

Timeline

• Start date: 2006-06-15
• Primary completion: 2007-06-15
• Completion: 2007-07-15
• First posted: 2018-08-10
• Last updated: 2018-08-10

Regulatory

• FDA-regulated drug study